Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (May 2017)
35 slides from Prescient Therapeutics's investor presentation, May 16, 2017
Slide 1: Investor Presentation (ASX Release)
ASX Release Investor Presentation Melbourne, Australia (16 May 2017): Prescient Therapeutics Ltd (ASX: PTX) is a clinical-stage oncology company focused on identifying, developing and commercializing novel cancer treatments to serve unmet needs has today released an updated investor presentation ahe
Slide 2: Two Novel Targeted Therapies Yielding a Deep Oncology Clinical Pipeline
TWO NOVEL TARGETED THERAPIES YIELDING A DEEP ONCOLOGY CLINICAL PIPELINE Prescient Therapeutics Limited (ASX: PTX) Broker presentation May 2017
Slide 3: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 4: Company Overview
COMPANY OVERVIEW 3 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 5: Investment Highlights
INVESTMENT HIGHLIGHTS 2 DRUGS » 3 TRIALS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • 2 targeted therapies with impeccable scientific pedigree • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials • One of deepest clinical pipelines on the ASX » Targeting
Slide 6: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE • PTX-200 currently in three clinical trials • Focus is now on further development of PTX-100 in rare hematological cancers DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 PTX-200 BREAST CANCER Underway PTX-200 OVARIAN CANCER Underway PTX-200 A
Slide 7: Corporate Snapshot
CORPORATE SNAPSHOT KEY METRICS ASX Ticker PTX Market Capitalisation1 A$20 M (US$14.8 M) Total Issued Capital 211.3 M shares Cash Position2 A$8.7 M (US$6.4 M) Options 57.8 M Top 20 Own 52% Share Price1 A$0.093 (US$0.069) 6 month turnover1 56.7 M shares; A$6.0 M (US$4.3 M) SHARE PRICE PERFORMANCE SHAR
Slide 8: How Our Drugs Work: Molecular Switches
HOW OUR DRUGS WORK: “MOLECULAR SWITCHES” Akt & Ras are growth molecules found in cells – when they are stuck “on”, they send constant signals to the cancer cell to grow PTX’s drugs block the Akt & Ras growth pathways, PTX-100 switching the growth signals off and causing the cancer cell to die PTX-20
Slide 9: World Class Centers & Collaborations
WORLD CLASS CENTERS & COLLABORATIONS CONNECTICUT NEW YORK FLORIDA PREVIOUS CLINICAL TRIALS CONDUCTED AT: 8 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 10: Drugs Don't Develop Themselves!
DRUGS DON’T DEVELOP THEMSELVES! PTX DEVELOPMENT TEAM WITH BENCH TO BEDSIDE SUCCESS Proven success from discovery and clinical development, through to FDA approvals • Professor and Chair, Department of Drug Discovery - Moffitt Cancer Center Said Sebti, PhD • Co-inventor of PTX-100 & PTX-200 Chief Sci
Slide 11: PTX-200
PTX-200 NOVEL AKT INHIBITION AML Breast cancer Ovarian cancer 10 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 12: Akt Is a Master Switch for Cellular Growth & Survival
AKT IS A MASTER SWITCH FOR CELLULAR GROWTH & SURVIVAL 11 ERSAHIN, T. ET AL; MOL. BIOSYST., 2015,11, 1946-1954
Slide 13: PTX-200: Novel Akt Inhibition via PH Domain Binding
PTX-200: NOVEL AKT INHIBITION VIA PH DOMAIN BINDING • Akt must be bound to the plasma membrane to be activated • PTX-200 prevents Akt binding to plasma membrane by binding to the PH domain, thereby inactivating Akt • This approach has an advantage over other Akt attempts, which are ATP mimic/direct
Slide 14: Acute Myeloid Leukemia Overview
ACUTE MYELOID LEUKEMIA OVERVIEW • AML is a type of cancer that affects the blood and bone marrow » Patient cannot produce normal blood cells » Blood cells cannot function properly nor fight disease • Progresses very quickly; 5 year survival only 25% • More common in adults over 60 years old, so the
Slide 15: PTX-200 in AML – Overview
PTX-200 IN AML – OVERVIEW • Akt is highly relevant in AML (high pAkt = inferior survival) • PTX-200 address 72% of AML mutations • Like other recent successful strategies in AML, PTX-200 is a targeted therapy complementing a “backbone” of standard chemotherapy (cytarabine) • PTX-200 synergizes with
Slide 16: Spectacular Story of Celator Pharmaceuticals
SPECTACULAR STORY OF CELATOR PHARMACEUTICALS • Celator (NASDAQ: CPXX) soared to ~$780M valuation on positive Phase 3 data in AML (naïve/newly diagnosed secondary AML) 31 March 2016 • Jazz Pharmaceuticals announced US$1.5B cash takeover of CPXX on 31 May 2016 • Reformulation of existing standard of c
Slide 17: Phase 1b AML Trial Underway
PHASE 1B AML TRIAL UNDERWAY • Phase 1 results with PTX-200 (monotherapy) very encouraging • Now PTX-200 + cytarabine in refractory or relapsed acute leukemia » 15 -18 patients » 3+3 design, single arm » Up to 4 dose levels of PTX-200 starting at 25 mg/m2 (days 1, 8, 15) » Cytarabine held constant at
Slide 18: Breast Cancer Overview
BREAST CANCER OVERVIEW • Breast cancer market currently US$10 B; due to double by 2023 • Most breast cancer drug sales are for HER2+ cancers, but this only represents ~20% of all breast cancers • By contrast, HER2- has “flown under the radar” of drug developers, due to high profile successes in HER2
Slide 19: Phase 1b Breast Cancer Trial Successfully Completed
PHASE 1B BREAST CANCER TRIAL SUCCESSFULLY COMPLETED • PTX-200 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide) • Patients with metastatic and locally advanced HER2- breast cancer » Albert Einstein College of Medicine Montefiore Medical Center and the H. Lee Moffitt Can
Slide 20: Ovarian Cancer Overview
OVARIAN CANCER OVERVIEW • One of the most common cancers in women - increasing with an ageing population • Due to reach US$1.7 B by 2019 » Market size currently constrained by old generic drugs that just aren’t good enough • Standard of care has not changed in decades (often generic paclitaxel & car
Slide 21: Phase 1b Ovarian Cancer Trial Underway
PHASE 1B OVARIAN CANCER TRIAL UNDERWAY • Significant need for new products to treat platinum-resistant ovarian cancer • Testing PTX-200 plus carboplatin in patients with platinum resistant ovarian cancer • PTX-200 already proven overcome cisplatin resistance and synergize with cisplatin in pre-clini
Slide 22: PTX-100: First in Class Inhibitor of Ras Pathway
PTX-100 FIRST IN CLASS INHIBITOR OF RAS PATHWAY Phase 1 in solid tumors completed; Now planning a transformative trial in rare heme cancers 21 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 23: Ras Pathway Is an Important but Elusive Target
RAS PATHWAY IS AN IMPORTANT BUT ELUSIVE TARGET GROWTH FACTOR • Ras mutated in 30% of all human cancers and 90% RECEPTOR TYR KINASE in certain cancers » A staggering 3 million new cancers diagnosed worldwide Grb2 SoS each year with Ras mutations Ras FGTI • Mutant Ras tumors are often unresponsive to
Slide 24: PTX-100 Is a Highly Effective Anti Tumor Agent
PTX-100 IS A HIGHLY EFFECTIVE ANTI TUMOR AGENT IN PRE-CLINICAL MODELS AND FRESH PATIENT BIOPSIES Lung tumor1 • PTX-100 inhibits tumor growth and metastasis, 1200 induces tumor regression, and increases 1000 Vehicle survival in various mouse models: 800 » Inhibits tumor growth in human lung, 600 brea
Slide 25: PTX-100: Completed Phase 1 in Advanced Solid Tumors
PTX-100: COMPLETED PHASE 1 IN ADVANCED SOLID TUMORS Patients • 13 Trial Centers • University of Pennsylvania & Indiana University • Heavily pre-treated patients with refractory, advanced solid tumors Patient » 5 rectal; 5 colon; 1 hepatocellular; 1 carcinoid; 1 esophageal Inclusion • Median 4 prior
Slide 26: Rare Diseases Can Transform Smaller Companies
RARE DISEASES CAN TRANSFORM SMALLER COMPANIES • Rare diseases (<200,000 patients in US) can present big opportunities for smaller companies • Markets may be too small for some Big Pharma, but are big enough to transform smaller companies » e.g. Folotyn (Spectrum Pharmaceuticals) » For relapsed & ref
Slide 27: Big Opportunity in Rare Hematological Niche
BIG OPPORTUNITY IN RARE HEMATOLOGICAL NICHE • Recent research has revealed that a certain mutation (mutation X) is a key driver in certain haematological cancers • Some of these conditions are characterized by: » Being rare » Having poor prognoses with short median survival » Very few existing treat
Slide 28: PTX-100 the Most Advanced Drug Targeting Mutation in Question
PTX-100 THE MOST ADVANCED DRUG TARGETING MUTATION IN QUESTION PTX-100 • Only 12 oncology drugs in development in 1 addressing mutation X » No others are in the clinic NO. OF DRUGS IN DEVELOPMENT » None are in hematology indications » PTX-100 is the most advanced ADDRESSING MUTATION X 7 • PTX-100 has
Slide 29: Value Proposition
VALUE PROPOSITION 28 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 30: PTX Operates in Areas with Rich Deal Activity
PTX OPERATES IN AREAS WITH RICH DEAL ACTIVITY Deals1 since Jan 2016 Median deal size # transactions (US$M) Breast cancer2 30 255 AML 44 143 Ovarian cancer 36 234 Rare diseases (oncology)3 972 154 1. Deals defined as mergers, acquisitions, licenses and strategic alliances 2. Breast cancer deals only
Slide 31: Significant Valuation Arbitrage
SIGNIFICANT VALUATION ARBITRAGE Significant valuation arbitrage …Arbitrage against US AML peers is even against comparable ASX peers… 1,000 more pronounced 900 800 400 700 350 MARKET CAP US$M 600 300 MARKET CAP A$M 500 250 ASX peer average A$181M 400 200 300 US AML peer average US$254M 150 200 100 1
Slide 32: Continuing to Deliver Meaningful Progress
CONTINUING TO DELIVER MEANINGFUL PROGRESS RECENT PROGRESS PLANNED UPCOMING ACTIVITIES PTX-200 PTX-200 AML: Phase 1b study initiated at Moffitt and Yale; • AML: Completion of second cohort first cohort successfully completed Breast Cancer: Phase 1b completed and Phase 2 • Breast cancer: Phase 2 i
Slide 33: Investment Highlights
INVESTMENT HIGHLIGHTS 2 DRUGS » 3 TRIALS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • 2 targeted therapies with impeccable scientific pedigree • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials • One of deepest clinical pipelines on the ASX » Targeting
Slide 34: Investment Decision Funnel for Any Biotech
INVESTMENT DECISION FUNNEL FOR ANY BIOTECH Is the drug in a clinical trial, or still pre-clinical? Both drugs clinical stage Is the trial conducted to US FDA standard? All INDs (under US FDA) Do the indications make clinical & Targeting unmet/poorly met medical commercial sense? needs – relaps
Slide 35: Contact
CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 34 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Investor Presentation (May 2017) on 6ix